It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We connect data, design, and decision-making through secure, AI-driven platforms, giving you real-time visibility and collaboration that accelerates discovery and reduces cycle times across the entire drug discovery process.
Informatics is essential to early-stage drug discovery, transforming complex biological and chemical data into actionable insights, enabling smarter target selection, compound design, and faster, more informed decision making.
Our informatics platforms support every stage of the Design –Make –Test –Analyze (DMTA) cycle. From AI-driven compound design to secure data capture and inventory tracking, we employ scalable, cloud-based tools that drive collaboration, compliance, and innovation.
Sharing results in real time is central to our approach, it stimulates discussion, facilitates problem solving, and enables our project teams to make timely decisions. That’s why we’ve invested in a robust, cutting-edge services infrastructure that prioritizes seamless data integration, giving customers global visibility into their projects at any point, so you stay connected and in control.
Our Informatics Solutions
Sygnature Discovery’s informatics services combine AI-powered design, centralized workflow management, digital chemistry records, real-time inventory tracking, and expert support to accelerate the DMTA cycle, enhance collaboration, and turn complex data into actionable insights across the drug discovery process.
SygDesign: AI-Powered Compound Design
SygDesign is our AI-powered compound design platform, enabling chemists to generate, evaluate, and refine molecules with real-time feedback on synthetic feasibility. Built on a modern MLOps infrastructure, it integrates seamlessly into ELNs.
Idea Tracker: Centralized Workflow Management
Our Idea Tracker platform centralizes the entire Design–Make –Test –Analyse (DMTA) workflow, linking design hypotheses, synthesis progress, and analytical results in one secure environment. Built on a scalable, cloud-based infrastructure, it enhances collaboration, ensures traceability, and accelerates decision-making through real-time data access and integrated analytics.
Our ChemELN provides a secure, centralized digital record of all synthetic chemistry activities. It ensures data traceability, patent-ready documentation, and seamless integration with analytical and registration systems; empowering transparent, collaborative science.
Built on Dotmatics, our inventory solution enables real-time tracking of compound samples across multiple sites. With barcode integration, ELN connectivity, and centralized data indexing, it enhances traceability, reduces costs, and supports global collaboration.
Dotmatics Support: Expert Configuration and Integration
As a certified Dotmatics partner with over a decade of experience, we offer expert configuration, integration, and support. Our team helps clients unlock the full potential of Dotmatics, transforming raw data into strategic insights across the DMTA spectrum.
All our scientists have access to Elsevier’s cutting-edge chemistry platform, Reaxys, for scientific literature and patent searching capabilities and retrosynthesis scoping, ensuring informed decisions at every stage of discovery.
Key Benefits
Sygnature’s informatics solutions deliver transparent collaboration, real-time lifecycle visibility, and AI-driven design tools that accelerate compound prioritization and streamline drug discovery.
Secure and Transparent Informatics
Our role-based access, audit trails, and client-facing dashboards ensure secure, transparent communication across internal teams and external partners.
Real-Time Decision Making
With centralized platforms that connect design ideas, synthesis progress, and analytical results, we enable real-time decision-making and full traceability across the drug discovery lifecycle.
Accelerated Drug Discovery
Our SygDesign platform empowers chemists with predictive modelling, synthetic feasibility feedback, and expert-in-the-loop design: accelerating compound prioritization and reducing cycle times.
Ting Qin, Sergio Ernesto Ruiz Hernandez, Jason Shiers, Matthew Crittall, Andrew Novak, Colin Sambrook Smith Abstract Within a growing drug discovery company, scientists acquire (either through in house…
Discover how Sygnature Discovery integrates machine learning into HPLC purification, transforming a data-heavy process into a streamlined, automated workflow. This innovation achieves 95% method selection accuracy, saving time and ensuring high-quality compounds for clients.
Blog
FAQs
We provide integrated platforms for managing the DMTA cycle, including electronic lab notebooks (ChemELN), chemical inventory systems, AI-driven compound design (SygDesign), and centralized workflow tracking tools.
Our SygDesign platform supports predictions for physicochemical properties and ADMET/DMPK endpoints using both local and global machine learning models.
With over 10 years of experience and Dotmatics certified partner status, we specialize in configuring and optimizing Dotmatics for drug discovery workflows, ensuring cost-effective, compliant, and scalable solutions.
Our informatics platforms enable real-time data sharing, role-based access control, and integrated dashboards. These features ensure both internal teams and external partners are always aligned, working from the most current information to support timely, informed decision-making.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Delivering co-located, multidisciplinary drug discovery programs that combine speed, precision, and scientific rigor to advance candidates with confidence.
Our Computer Aided Drug Design (CADD) capabilities combine deep scientific expertise with advanced AI, machine learning, and informatics infrastructure to support smarter, faster decision-making across the drug discovery pipeline.
